Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:27 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Milnacipran (Savella) in Irritable Bowel Syndrome (IBS)
NCT01471379 · Spencer Dorn, MD, MPH · PHASE2 · terminated · last registry update 2017-04-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Due to recruitment difficulties the study is terminated.” | – | Registry record, Spencer Dorn, MD, MPH |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SLC6A4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-02-15Phase 3 first posted: Janssen Research & Development, LLC, Esketamine 56 mg + Esketamine 84 mg (NCT03434041)
- 2017-04-11Phase 3 first posted: JHSPH Center for Clinical Trials, Escitalopram + Placebo (NCT03108846)
- 2017-03-13Phase 3 first posted: University of Texas Southwestern Medical Center, Naltrexone: Vivitrol® + Placebo (PLB) Injectable (NCT03078075)
- 2016-05-26Phase 3 first posted: University Hospital, Lille, Ketamine + Milnacipran (NCT02783430)
- 2016-04-26Phase 3 first posted: Orygen, Fluoxetine + Placebo (NCT02751632)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision